Mark Corrigan BA, MD

Dr. Corrigan Co-Founded Tremeau in 2016. From 2010 to 2014, he served as a Director, President and Chief Executive Officer of the public company, Zalicus Inc. prior to their merger with Epirus Biopharmaceuticals in July 2014. Dr. Corrigan also serves on the Boards of Cardiome, CoLucid, Nabriva, Quartet Medicine and is Chairman of the Board of BlackThorn Therapeutics.

Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) and served as their executive vice president of research and development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine where he oversaw the development and registration of Celebrex among other medicines.

Before Dr. Corrigan entered the pharmaceutical industry, he spent five years in academic research at the University of North Carolina, School of Medicine and maintains a faculty appointment as Adj. Prof. in the Psychiatry Dept. He is a Distinguished Fellow of the American Psychiatric Association.

Dr. Corrigan had served on the board of directors of Cubist Pharmaceuticals where he chaired the Scientific Committee and of Avanir Pharmaceuticals, Inc. where he also served as their chair of the SAC. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.